1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Care Facilities
Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA

FRE.SW
Fresenius SE & Co. KGaACH flagSwiss Exchange
35.86
CHF
- -
- -
10.62BMarket Cap
Fresenius SE & Co. KGaA
FRE.SW
(Swiss Exchange)

Recent

price

35.86

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
32.86
33.44
37.1
37.86
42.91
50.7
53.84
61.04
60.24
63.47
64.96
67.23
38.36
37.4
38.98
40.61
31.22
Revenue per Share
2.48
1.41
1.78
1.88
1.97
2.49
2.85
3.27
3.64
3.38
3.06
3.26
2.44
-1.05
0.84
2.24
2
Basic EPS, GAAP
2.38
-0.86
-1.99
-2.71
-1.8
2.65
2.32
-7.52
0.94
-1.22
6.13
3.64
3.61
5.63
2.46
1.91
1.85
Free Cash Flow per Basic Share
0.68
0.75
0.86
0.91
1.08
1.17
1.35
1.66
1.62
1.71
1.9
1.91
0.72
0.98
- -
1.21
1
Dividend per Share
0.41
0.36
0.1
0.35
0.78
1.52
2.05
0.28
0.41
0.66
-1.03
1
1
1
1
1
1
Book Value per Share
-7.41
-5.63
-6.04
-4.35
-9.51
-7.49
-6.97
-12.14
-6.89
-9.01
-7.72
-6.25
-6.43
3.61
4.94
5.42
6.58
Tangible Book Value per Share
486
489
520
537
541
545
547
555
557
558
558
558
561
563
563
563
562
Basic Weighted Avg Shares
15,972
16,361
19,290
20,331
23,231
27,626
29,471
33,886
33,530
35,409
36,277
37,520
21,532
21,067
21,954
22,873
17,555
Sales/Revenue/Turnover
15.14
15.67
15.46
14.71
13.4
14.03
14.6
13.47
13.25
13
12.09
11.08
8.42
5.62
9.44
9.54
9.28
Operating Margin (%)
639
674
776
843
937
1,115
1,215
1,437
1,494
2,452
2,715
2,667
1,157
1,400
1,239
1,120
853
Depreciation Expense
1,205
690
926
1,011
1,067
1,358
1,560
1,814
2,027
1,883
1,707
1,818
1,372
-594
471
1,264
1,126
Net Income, GAAP
32.53
31.26
27.56
27.79
27.87
29.58
28.06
22.67
20.37
22.57
24.24
22.81
23.48
62.74
31.51
26.6
27.34
Effective Tax Rate (%)
7.54
4.22
4.8
4.97
4.59
4.92
5.29
5.35
6.05
5.32
4.71
4.85
6.37
-2.82
2.15
5.53
6.41
Profit Margin (%)
724
1,163
2,915
1,949
2,924
3,131
2,665
1,939
1,515
1,380
2,659
2,399
4,621
3,190
2,437
2,644
2,531
Working Capital
2,369
7,773
10,300
10,984
13,693
13,607
12,843
16,143
14,040
21,750
22,243
22,383
24,727
13,249
10,805
10,462
9,538
LT Debt
8,844
10,894
13,156
13,732
16,164
18,950
20,849
21,720
25,008
26,580
26,023
29,288
32,218
19,651
20,290
19,767
20,465
Total Equity
11.33
10.48
9.59
8.51
7.79
8.42
8.99
9.31
8.33
7.25
6.27
5.91
2.38
0.92
4.09
4.88
3.6
Return on Invested Capital (%)
22.24
3.96
4.06
4.21
4.12
4.45
3.9
4.94
3.87
4.28
3.23
3.6
2.28
2.47
6.41
10.84
7.73
Return on Capital (%)
1,131.46
368.98
815.86
849.58
349.26
217.45
160.33
284.1
1,058.49
635.08
- -
- -
244.78
-105.51
83.66
224.51
200
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
1,471
2,367
LT Borrowings
- -
9,220
8,311
LT Finance Leases
- -
1,242
1,227
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
563
563
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
11,027
12,068
Cash, Cash Equivalents & STI
- -
1,307
3,949
Accounts Receivable, Net
- -
3,558
3,962
Inventories
- -
2,611
2,730
Total Current Liabilities
- -
8,383
9,537
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,471
2,367
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.77%
-3.16%
-2.58%
Free Cash Flow
-145.01%
-12.63%
-22.35%
Net Income, GAAP
-14.58%
-34.45%
168.37%
Sales/Revenue/Turnover
-0.43%
-6.59%
4.19%
Total Cash Common Dividend
- -
- -
24.14%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,350
5,440
5,315
5,630
21,954
2025
5,706
5,581
- -
6,156
22,873
2026
5,818
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.49
-0.66
0.58
- -
0.84
2025
0.41
0.58
- -
- -
2.24
2026
0.77
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
0.17
0.98
- -
- -
1.21
2026
- -
- -
- -
- -
- -
Similar Companies
Medgroup Inc. (MDGP)
Specialized Medical Company (4019.SR)
IHH Healthcare Berhad (IHHHF)
Life Healthcare Group Holdings Limited (LTGHY)
Cano Health, Inc. (CANO-WT)
Fresenius SE & Co. KGaA (FRE.SW)
Business
Fresenius SE & Co. KGaA is a global healthcare company headquartered in Bad Homburg vor der Höhe, Germany, specializing in products and services for critically and chronically ill patients. The company operates through four main segments: Fresenius Medical Care, the world’s leading provider of dialysis products and services including dialyzers, hemodialysis machines, and related disposables; Fresenius Kabi, which supplies essential drugs, clinical nutrition products, intravenous generic drugs for oncology and other therapies, and medical devices; Fresenius Helios, the largest hospital operator and provider of inpatient and outpatient services in Germany with over 110 hospitals; and Fresenius Vamed, which focuses on engineering, construction, and management of healthcare facilities. Fresenius offers a comprehensive portfolio including biopharmaceuticals, biosimilars, MedTech solutions, and care provision services across Europe, the Americas, and Asia. Recent major changes include Fresenius Medical Care’s initiation of a share buyback program in 2025 with Fresenius maintaining around a 25% stake, expansion of its biosimilars portfolio with new approvals and launches in Europe and the U.S., strategic licensing agreements for autoimmune biosimilars, and continued investment in AI technologies and new hospital infrastructure such as the opening of the Helios HSK Kliniken in Wiesbaden, Germany. The company targets healthcare providers and patients globally and emphasizes innovation and sustainability in its therapy platforms including biopharma, MedTech, and care provision. Founded in 1912, Fresenius continues to evolve into a more therapy-focused organization catering to major healthcare trends with approximately 176,000 employees and annual revenues exceeding €21 billion as of 2024.